Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation
This book is the first to offer a comprehensive examination of the pharmaceutical industry by following the tortuous course of a new drug as it progresses from early development to final delivery. Richard A. Epstein looks closely at the regulatory framework that surrounds all aspects of making pharmaceutical products today, and he assesses which current legal and regulatory practices make sense and which have gone awry.
While critics of pharmaceutical companies call for ever more stringent controls on virtually every aspect of drug development and approval, Epstein cautions that the effect of such an approach will be to stifle pharmaceutical innovation and slow the delivery of beneficial treatments to the patients who need them. The author considers an array of challenges that confront the industry--conflicts of interest among government, academe, and the drug companies; intellectual property rights that govern patents; FDA regulation; pricing disputes; marketing practices; and liability issues, including those brought to light in the recent VIOXX case. Epstein argues that to ensure the continuing creativity, efficiency, and success of the pharmaceutical industry, the best system will feature strong property rights and clearly enforceable contracts, with minimal regulatory and judicial interference.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Externalities Coordination and the Public
Maintaining the PublicPrivate Interface
Intellectual Property and Its Regulation
12 other sections not shown
Other editions - View all
action addition adverse advertisements allow basic Bayh-Dole benefit billion causation Celebrex claim clinical trials compensation competition conflicts of interest consumer court critical deadweight losses decision design-defect drug companies efforts Epstein Ernst expenditures FDA's federal firms fraud funds harm holdout problem increase individual initial institutions intellectual property inventions Iressa issue jury license litigation manufacturer Marcia Angell marginal cost matter Merck Metformin monopoly naproxen needed overall particular patent protection patent system percent person Pfizer pharmaceutical companies pharmaceutical industry physicians plaintiff position potential prescription drug price discrimination problem product liability property rights proposal public domain purchase question refund regime regulation regulatory requires response revenues Rezulin risk Rofecoxib rules safety sensible side effects social sumer tion tort system transaction treatment United users Vioxx Wall Street Journal warnings